Targeting perioperative period in Osteosarcoma by use of Propranolol and Celecoxib with Receptor activator of nuclear factor kappa-Ã?â?? ligand (RANKL) blockade Ã¢â?¬â?? A phase II randomized controlled study.

Tata Memorial Hospital0 个研究点目标入组 0 人开始时间: 待定最近更新: 2022年10月17日

试验速览

暂无简介。

•1. Age > 12 years
•2. Histologically diagnosed, treatment naive, non-metastatic osteosarcoma patients planned
•for curative intent treatment.
•3. Duration from biopsy to starting of chemotherapy less than or equal to one month.
•4. Have consented to undergo perioperative treatment (propranolol and celecoxib with
•denosumab) after adequate staging workup.

•1. Patients with metastatic disease at presentation.
•2. Any prior local or systemic treatment
•3. Contraindication to use study medications.
•Ã¯â??Â§ Propranolol:
•a) Cardiogenic shock;
•b) Sinus bradycardia and greater than first-degree block;
•c) Bronchial asthma; and
•d) In patients with known hypersensitivity to Propranolol hydrochloride.
•Ã¯â??Â§ Celecoxib:
•a) Patients with known hypersensitivity to celecoxib, aspirin, or other
•b) History of IHD
•c) In patients with active gastrointestinal bleeding.
•Ã¯â??Â· Denosumab
•a) Severe uncorrected hypocalcemia
•b) prior history of osteonecrosis or osteomyelitis of the jaw, an active dental
•or jaw condition requiring oral surgery, non-healed dental/oral surgery, or
•any planned invasive dental procedure

发起方